Updated:
atai Life Sciences
Florian Brand runs atai Life Sciences, a Nasdaq-listed platform developing psychedelic therapies for mental-health disorders via a subsidiary structure.
atai Life Sciences
Florian Brand co-founded atai Life Sciences in 2018 alongside entrepreneur Christian Angermayer, creating a holding company structure that incubates and finances drug development for mental-health indications. The firm was listed on Nasdaq in 2021 via a SPAC merger with Newbury Street Acquisition Corp (per the firm, 2021). Wealth origins trace to Angermayer's prior biotechnology and investment ventures, though the firm discloses no single-family-office backing. atai's strategy targets the development of psychedelic compounds, including psilocybin, MDMA, and DMT analogs, for disorders such as treatment-resistant depression, PTSD, and anxiety. The firm operates more than a dozen majority-owned subsidiaries, each focused on a specific compound or indication, including Compass Pathways and Small Pharma (per public filings). Its geographic footprint is primarily US and European based, with clinical trials conducted across multiple countries. The firm went public via SPAC in 2021, raising $175M in gross proceeds (per SEC filings, 2021). As of 2024, atai had not received approval for any marketed drug. Brand serves as CEO; Dr. Srinivas Rao leads clinical development. The firm maintains a non-profit-oriented access model through its VITAL program, which aims to ensure affordability if drugs are approved (per the firm's public statements, 2023). atai's structural differentiator is its hybrid model combining non-profit patient-access commitments with a for-profit public-company structure — a governance choice that pressures traditional pharma timelines but aligns with impact-focused investor mandates. The firm's holding-company approach allows it to spread trial risk across multiple compounds without betting the enterprise on a single molecule.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Berlin
Corporate office
Berlin, Germany
Principals
Florian Brand
CEO
Christian Angermayer
Chairman of the Board
Dr. Srinivas Rao
Chief Medical Officer
Sector focus
Frequently asked questions
Who runs investment decisions at atai Life Sciences?
CEO Florian Brand leads the company, with strategic direction from Chairman Christian Angermayer. Clinical investment decisions are overseen by Chief Medical Officer Dr. Srinivas Rao. The board includes scientific advisors from the psychedelic research community.
Is atai Life Sciences a family office, a drug company, or an investment platform?
atai is a publicly traded biotechnology company (Nasdaq) that operates as a drug-development platform. It is not a family office. Its structure — a holding company with majority-owned subsidiaries — mirrors a venture-incubator model applied to clinical-stage drug development.
How does atai source and fund its subsidiaries?
atai identifies academic research or early-stage compounds targeting mental-health disorders, then forms or acquires companies around each asset. It provides initial funding, scientific support, and clinical trial management. Notable subsidiaries include Compass Pathways (psilocybin) and Small Pharma (DMT), per public filings.
What investment stages does atai typically target?
atai focuses on preclinical to Phase 2 clinical-stage compounds. Its model is designed to advance multiple assets through early clinical proof-of-concept before seeking partnerships or later-stage funding from larger pharmaceutical companies.
Does atai have a non-profit or impact mandate?
Yes. atai established the VITAL program, which commits that any approved therapy developed by the firm will be made available at affordable, not-for-profit pricing. This is a legally binding commitment for certain assets, per the firm's public statements.
Where does the underlying wealth come from at atai?
The wealth backing atai originates primarily from Christian Angermayer's prior ventures in biotechnology and investment. Angermayer is a serial entrepreneur in the life sciences space, and the firm's SPAC provided public-market capital. No single-family-office endowment is disclosed.
Which sectors does atai explicitly avoid?
atai does not invest in non-psychiatric pharmaceutical indications, medical devices, diagnostics, or platform technologies outside mental health. Its stated focus is exclusively on psychedelic-assisted therapies for psychiatric disorders.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: